INTRODUCTION AND OBJECTIVES: Our recent studies have revealed that adipocytokines secreted by adipocytes are important for the formation of kidney stones. b3-adrenergic receptor agonist is reported to differentiate white adipocytes into beige cells, which improves metabolic syndrome via the specific protein uncoupling protein 1 (UCP1) expression. In this study, we investigated the effect of transdifferentiation from white adipocytes to beige cells on kidney stone formation.
INTRODUCTION AND OBJECTIVES: Kidney stone disease has emerged to an important worldwide socioeconomic issue. Although EAU and AUA guidelines suggest optimizing nutrition habits, metaphylaxis fails due to low compliance rates. Therefore, we developed a mobile application (app) for patients with kidney stones to increase the compliance in stone metaphylaxis.
METHODS: To identify the most appropriate design and structure of the app, we searched through the English and German versions of the App Store and the Google Play Store. To combine all relevant information for the app, we performed a literature research using PubMed, Google Scholar and clinical recommendations of EAU and AUA.
RESULTS: The mobile app "StoneMD" was created by urologists and programmers and is available in the English, German and Russian App Store and Google Play Store. The app includes the following features: 1) "Test" -individual calculation of the stone recurrence risk according to the ROKS nomogram based on individualized recommendations with regard to the AUA guidelines on medical management of kidney stones and calorie intake requirements.2) "Water balance" -automatic registration of fluid intake with push-notifications about the necessity to drink water.3) "Food" -information of the content of calcium, oxalate, purine, protein, citrate, and calories in foods and drinks counting up to 800 products. The selected products can be used as information or can be added to a cart to get the amount of ingredients in total.4) "pH diary" e the patient selects the recommended pH range and types in the results of urine pH according to the colors on the smartphone.5) "Stent radar" -designed to track the date of ureteral stent insertion, its laterality, and the date of extraction/change to avoid forgotten ureteral stents.
CONCLUSIONS: "StoneMD" is the first mobile app for stone metaphylaxis including all relevant information of alimentation, an installed urinary pH diary and a stent tracker. The StoneMD app might help to improve patients' compliance and might lower the risk of stone formation. METHODS: ChIP assay and luciferase assay demonstrated that VDR suppressed Slc26a6 expression via directly regulating miR-125b.
RESULTS: Here, we showed that VitD3 mediated intestinal oxalate secretion and CaOx stone formation via a VDR-miR-125b-Slc26a6-based pathway in vivo and in vitro. First, we demonstrated that VitD3 regulated intestinal oxalate secretion and promoted glyoxylateinduced CaOx crystals formation in a VDR-dependent manner. Using miRNA microarray analysis, we found that miR-125b was significantly induced by 1,25-(OH)2D3 in Caco-2 cells. Chromatin immunoprecipitation assays demonstrated VDR-positive transcriptional activation of miR-125b. MiR-125b in turn inhibited VDR by targeting its 3'-UTR. Notably, this negative feedback loop was broken by the single nucleotide polymorphisms (SNP) rs55774542 in the interaction between miR125b and VDR 3'-UTR, which altered susceptibility to kidney stones. Additionally, we found that miR-125b regulated endogenous 1,25-(OH) 2D3 levels by directly targeting CYP24A1. Luciferase assays verified that miR-125b directly targeted the 3'-UTR of Slc26a6.
CONCLUSIONS: Together, our results defined a novel signaling cascade in VitD3-mediated intestinal oxalate imbalance via regulation of the VDR-miR-125b-Slc26a6 pathway, which promoted CaOx crystals formation.
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